May 18 — Endo International Plc agreed to buy Par Pharmaceutical Holdings Inc. for $8.05 billion in cash and stock as part of a plan to ignite sales growth and pursue more acquisitions. Sonenshine Partners Chairman Marshall Sonenshine and Bloomberg’s Ed Hammond speak on “Bloomberg Markets.” Watch
Researchers get NSF funding to create virtual-heart platform to improve medical device development
A virtual-heart platform proposed by Stony Brook researchers and colleagues to improve and accelerate medical-device development and testing has received funding from the National Science Foundation (NSF) in the amount of $4.2 million over five years.
The “Cyberheart” project, led by Scott Smolka, a Professor of Computer Science at Stony Brook University, is part of the NSF’s center-scale initiative to advance the state-of-the-art in Cyber-Physical Systems (CPS): engineered systems that are built from, and depend upon, the seamless integration of computation and physical components. Often called the “Internet of Things,” CPS enable capabilities that go beyond the embedded systems of today. Read More
Agios Pharma (AGIO) Announces Receipt of FDA Fast-Track Designation for AG-120 as AML Treatment
Agios Pharma (NASDAQ: AGIO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-120 for the treatment of patients with acute myelogenous leukemia (AML) who harbor an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is a first-in-class, oral, selective, potent inhibitor of the mutated IDH1 protein being evaluated in two Phase 1 clinical trials, one in hematologic malignancies that recently initiated three expansion cohorts, and one in advanced solid tumors, including glioma. Read More